ShangBay Capital LLC — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Laplace Interventional develops a transcatheter tricuspid valve replacement system that delivers a prosthetic valve percutaneously, avoiding open-heart surgery for patients with tricuspid regurgitation.
HealthtechMedical DevicesPlymouth, US
Ramji Iyer(Executive Officer, Director)in
BoardJenny H. Barba(Director)Todd Mortier(Director)Colin Morrison(Director)
Co-investorsAphelion CapitalFeatures Capital Holdingsgener8torAphelion CardeationEngage Venture PartnersUnorthodox Ventures
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)in
BoardBlake Wu(Director)inJuan-Pablo Mas(Director)in
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersCatalio Capital Management, LPCitta Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.